Chester County News and Community Website
BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that the first patient in a trial to test the effectiveness of buntanetap on early Parkinson’s Disease was recently dosed.
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease Read More BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) recently announced second quarter financial results for the quarter ended June 30, 2022, and reviewed recent accomplishments.
Annovis Bio Expands Intellectual Property Portfolio Around PD Drug Candidate Read More BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that the Company recently received notice from the FDA that the Phase 3 clinical study in early Parkinson’s patients may proceed. The …
Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson’s Disease Read More